Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: meta-analyses of published studies
Madan G. Kundu, Suddhasatta Acharyya

TL;DR
This study evaluates how well progression-free survival (PFS) measures predict overall survival (OS) in metastatic breast cancer, finding that median PFS increase is a better predictor and that total deaths improve prediction accuracy.
Contribution
It provides a systematic analysis of PFS as a surrogate for OS, highlighting the predictive value of median PFS increase and the role of total deaths in metastatic breast cancer studies.
Findings
Median PFS increase (%ΔMED_PFS) is a better predictor of OS than hazard ratios.
Total number of deaths enhances the diagnostic accuracy of PFS measures.
Only 7.9% of cases with short PFS increase reported significant OS.
Abstract
Purpose: PFS is often used as a surrogate endpoint for OS in metastatic breast cancer studies. We have evaluated the association of treatment effect on PFS with significant HR (and how this association is affected by other factors) in published prospective metastatic breast cancer studies. Methods: A systematic literature search in PubMed identified prospective metastatic breast cancer studies. Treatments effects on PFS were determined using hazard ratio (HR), increase in median PFS (MED) and % increase in median PFS (%MED). Diagnostic accuracy of PFS measures (HR, MED and %MED) in predicting significant HR was assessed using receiver operating characteristics (ROC) curves and classification trees approach. Results: Seventy-three cases (i.e., treatment to control comparisons) from 64…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
